Hyperstable synthetic miniproteins as ligand scaffolds

Hyperstable synthetic miniproteins as modular ligand scaffolds for advanced therapeutics and diagnostics.

IP Status: PCT Pending; PCT/US2024/041439

Applications

- Molecularly targeted therapeutics
- Diagnostic tools
- Radiotherapy
- Biopharmaceuticals

Key Benefits & Differentiators

- **Enhanced Stability:** Superior stability compared to natural proteins, ensuring better performance under physiological conditions.
- **Improved Delivery:** Smaller size allows for better penetration in solid tumors, efficient blood vessel extravasation, and greater pharmacokinetic flexibility.
- Modularity: Facilitates the creation of multifunctional therapeutic agents like bispecific T-cell
 engagers (BiTEs), trispecific killer cell engagers (TriKEs), and antibody-drug conjugates (ADCs).
- **Reduced Background:** Faster clearance from non-targeted areas reduces toxicity during radiotherapy and ADC applications and reduces background in PET imaging.

Technology Overview

The development of targeted therapeutics and diagnostics is often limited by the structural complexity and size of antibodies, which can impede effective tumor penetration and physiological transport. Traditional ligands used in these applications frequently exhibit inefficient performance in complex molecular targeting, particularly in creating multifunctional agents such as BiTEs, TriKEs, and ADCs. These limitations necessitate the development of novel ligand scaffolds that are both stable and versatile, capable of enhancing the efficacy of targeted therapies and diagnostic tools.

Researchers at the University of Minnesota have developed hyperstable synthetic miniproteins (~40 amino acids) that function as versatile ligand scaffolds. Unlike natural protein sequences, these synthetic miniproteins are engineered to enhance molecular binding efficiency and stability. This innovation offers significant advantages in modularity, enabling the development of multifunctional therapeutic agents, improved tumor delivery, and simplified synthesis.

Phase of Development

TRL: 3-4

The researchers are currently validating dozens of scaffolds, thousands of binding ligands, and multiple biological targets.

Desired Partnerships

Technology ID

2023-269

Category

All Technologies
Life Sciences/Biologics
Life Sciences/Diagnostics &
Imaging
Life Sciences/Human Health
Life Sciences/Pharmaceuticals
Life Sciences/Research Tools
Life Sciences/Therapeutics

View online



This technology is now available for:

- License
- Sponsored research
- Co-development

Please contact our office to share your business' needs and learn more.

Researchers

• Ben Hackel, PhD Professor, Department of Chemical Engineering

References

- Adam McConnell, Sun Li Batten, and Benjamin J. Hackel(2023), https://www.sciencedirect.com/science/article/abs/pii/S0022283623004503?via%3Dihub, Journal of Molecular Biology, 435, Article 168339
- 2. Paul L. Blanchard, Brandon J. Knick, Sarah A. Whelan, and Benjamin J. Hackel(2023), https://pubs.acs.org/doi/10.1021/acssynbio.3c00409, ACS Synthetic Biology, 12, 3608-3622